

Proposal Writing Training for 2022 Collaborative Projects

Testimonial

Dr Ariel Beresniak MD, MPH, PhD



My organization (Swiss SME)



➤ **Independent research agency** Specialized of value demonstration of innovative solutions

- Value demonstration of innovative solutions
- Advanced data analytics and modelling
- Outcome research
- Health Economics
- Advanced methodologies in clinical research
- Risk Assessment

Involvement in European Commission projects



Tests the methodological robustness of the QALY indicator



Cost-effectiveness Models Development of European Influenza Human Pandemic Response Strategies



Electronic Health Records for Clinical Research



Semantic Interoperability for Health Network



Establishing the value and business model for sustainable eHealth services in Europe



Action plan on Science in Society related issues in Epidemics and Total pandemics

REMEDIA


Impact of the exposome in pulmonary diseases



Evaluator panel experience



Evaluation process



Evaluator guidelines

Please respect the following principles:

- Provide clear feedback on **the proposal's weaknesses and strengths**, of an adequate length, and in an appropriate tone.
- If you identify **shortcomings** (other than minor ones and obvious clerical errors), reflect those **in a lower score for the relevant criterion**.
- Explain the shortcomings **without recommendations for improvements**.
- For **proposals with significant weaknesses** that prevent the project from achieving its objectives, **please do not score these above-threshold**.
- When scoring, verify that **the wording and the chosen attributes** (and the retained shortcomings) **match the score**.

Final proposal's ranking in case of similar total score

Method to establish the priority order

For each group of proposals with the same score, starting with the group achieving the highest score and continuing in descending order:

- 1) **Proposals** that address **aspects** of the call that have **not been covered** by more highly ranked proposals.
- 2) **The scores** for 'Excellence' and then 'Impact'.
- 3) **Gender balance** among the personnel named in the proposal who will be primarily responsible for carrying out the research and/or innovation activities, and who are included in the **researchers table** in the proposal.
- 4) **Geographical diversity**, defined as the number of Member States or Associated Countries represented in the proposal, not otherwise receiving funds from projects higher up the ranking list (and if equal in number, then by budget).
- 5) **Other factors** set by the panel.

The topic

- **Complex deliverable from EU country representatives negotiation**
- **Various key words and tasks according to each country interest**
- **Often lead to very complex text**
- **Difficulty to address all ideas included into one topic**
- **Difficulty to assess the level of international competition**

Example :

Development of new effective therapies for rare diseases

TOPIC ID: HORIZON-HLTH-2022-DISEASE-06-04-two-stage

ExpectedOutcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “*Tackling diseases and reducing disease burden*”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to some of the following expected outcomes:

- Researchers and developers make the best use of the state-of-the-art knowledge and resources for a fast and effective development of new therapies for rare diseases.
- Researchers and developers increase the development success rate of therapies for rare diseases by employing robust preclinical models, methods, technologies, validated biomarkers, reliable patient reported outcomes and/or innovative clinical trials designs.
- Developers and regulators move faster towards market approval of new therapies for rare diseases (with currently no approved treatment option) due to an increased number of interventions successfully tested in late stages of clinical development.
- Healthcare professionals and people living with a rare disease get access to new therapeutic interventions and/or orphan medicinal products.

Example :

Development of new effective therapies for rare diseases

TOPIC ID: HORIZON-HLTH-2022-DISEASE-06-04-two-stage

ExpectedOutcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “*Tackling diseases and reducing disease burden*”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to some of the following expected outcomes:

- Researchers and developers make the best use of the state-of-the-art knowledge and resources for a fast and effective development of new therapies for rare diseases.
- Researchers and developers increase the development success rate of therapies for rare diseases by employing robust preclinical models, methods, technologies, validated biomarkers, reliable patient reported outcomes and/or innovative clinical trials designs.
- Developers and regulators move faster towards market approval of new therapies for rare diseases (with currently no approved treatment option) due to an increased number of interventions successfully tested in late stages of clinical development.
- Healthcare professionals and people living with a rare disease get access to new therapeutic interventions and/or orphan medicinal products.

Example :

Development of new effective therapies for rare diseases

TOPIC ID: HORIZON-HLTH-2022-DISEASE-06-04-two-stage

The proposals should address most of the following research activities:

- Establish multidisciplinary collaborations between all relevant stakeholders by integrating disciplines, technological developments and existing knowledge. Integrate harmonised data from multiple sources (i.e. natural history studies/clinical trials, multi-omics, medical imaging, registries etc.) by utilising data analytics and/or other suitable methods, with the aim to understand the pathophysiology/heterogeneity of the rare diseases concerned and to identify therapeutically actionable mechanisms.
- Develop and utilise relevant preclinical models and/or innovative tools/technologies to: verify molecular/cellular pathways/genes that can be therapeutically targeted, increase the confidence in the targets selection and/or perform toxicity studies. When using disease models the applicants should describe how well the model replicates the pathology or the human condition.
- Develop and/or execute innovative clinical trials designs for small populations and novel approaches to assess and monitor the safety and efficacy of the proposed interventions. Such approaches may include but are not limited to: biomarkers defining robust surrogate and clinical endpoints; artificial intelligence tools/medical devices/biosensors/ companion/ complementary diagnostics for defining reliable patient reported outcomes; modelling and simulation and in-silico trials methodologies.
- Carry out preclinical proof-of-concept (PoC) studies and/or multinational interventional clinical studies^[3] to demonstrate the safety and efficacy of the therapeutic interventions under study. Preclinical PoC studies should include late-stage preclinical studies (i.e. toxicological properties, adverse effects etc.). Clinical studies may cover all necessary development stages. Applicants should propose a clear exploitation pathway through the different necessary steps (research, manufacturing, regulatory approvals and licensing, IP management etc.) in order to accelerate marketing authorisation and uptake by the health systems.

Example :

Development of new effective therapies for rare diseases

TOPIC ID: HORIZON-HLTH-2022-DISEASE-06-04-two-stage

The proposals should address most of the following research activities:

- Establish multidisciplinary collaborations between all relevant stakeholders by integrating disciplines, technological developments and existing knowledge. Integrate harmonised data from multiple sources (i.e. natural history studies/clinical trials, multi-omics, medical imaging, registries etc.) by utilising data analytics and/or other suitable methods, with the aim to understand the pathophysiology/heterogeneity of the rare diseases concerned and to identify therapeutically actionable mechanisms.
- Develop and utilise relevant preclinical models and/or innovative tools/technologies to: verify molecular/cellular pathways/genes that can be therapeutically targeted, increase the confidence in the targets selection and/or perform toxicity studies. When using disease models the applicants should describe how well the model replicates the pathology or the human condition.
- Develop and/or execute innovative clinical trials designs for small populations and novel approaches to assess and monitor the safety and efficacy of the proposed interventions. Such approaches may include but are not limited to: biomarkers defining robust surrogate and clinical endpoints; artificial intelligence tools/medical devices/biosensors/ companion/ complementary diagnostics for defining reliable patient reported outcomes; modelling and simulation and in-silico trials methodologies.
- Carry out preclinical proof-of-concept (PoC) studies and/or multinational interventional clinical studies^[3] to demonstrate the safety and efficacy of the therapeutic interventions under study. Preclinical PoC studies should include late-stage preclinical studies (i.e. toxicological properties, adverse effects etc.). Clinical studies may cover all necessary development stages. Applicants should propose a clear exploitation pathway through the different necessary steps (research, manufacturing, regulatory approvals and licensing, IP management etc.) in order to accelerate marketing authorisation and uptake by the health systems.

Recommendation: Proposal building

- Track and select the KEY words and KEY sentences
- Address every KEYwords and KEY sentences of the topic
- Help the evaluator
 - Explain how each key sentences has been taken into account
 - Clear style and presentation: use colors and figures
- One single writer for homogeneous and consistant style
- A proposal is a convincing promess
 - Promess, promess, promess
- Select an easy-to-memorize project acronym in relation to the topic
 - MYHEALTH better than ACTHOMG

Excellence evaluation report

- Clarity and pertinence of the project's objectives,
- Extent to which the proposed work is ambitious
- How the project goes beyond the state of the art.
- Soundness of the proposed methodology
 - including the underlying concepts, models, assumptions, inter-disciplinary approaches, appropriate consideration of the gender dimension in research and innovation content,
 - quality of open science practices, including sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.

The objectives are clear as they are specific, measurable, achievable and realistic.
This is excellent

The objectives are (fully) pertinent and /or fully aligned with scope of the call
topic as the proposal aims to...

The proposal goes beyond the state of the art only in a limited way because ...

Impact evaluation report

- Credibility of the pathways to achieve the expected outcomes and impacts specified in the work programme, and the likely scale and significance of the contributions from the project.
- Suitability and quality of the measures to maximise expected outcomes and impacts, as set out in the dissemination and exploitation plan, including communication activities.

The project results will excellently *OR* very well *OR* well *OR* fairly *OR* poorly contribute to all *OR* most of the expected outcomes and impacts as set out in the work programme

The scale and significance of the project's contribution to the expected outcomes and impacts are excellently *OR* very well *OR* well *OR* fairly *OR* poorly estimated and quantified because ...For outcome X, the project results will contribute significantly because...

The proposed dissemination and/or exploitation measures are excellently *OR* very well designed, they are proportionate to the scale of the project and include a clearly specified set of actions and target groups

Quality and efficiency of the implementation

- Quality and effectiveness of the work plan, assessment of risks, and appropriateness of the effort assigned to work packages, and the resources overall.
- Capacity and role of each participant, and the extent to which the consortium as a whole brings together the necessary expertise.

The work plan is of high quality, it is logical and includes quantified information to allow the monitoring of progress.

The work plan reflects the proposed methodology in an excellent *OR* very good *OR* good way.

Tasks are excellently *OR* very well described and their outputs are clearly defined in terms of deliverables and timeframe.

The allocation of resources to work packages is excellently *OR* very well justified and they are in accordance with their objectives and deliverables

Critical risks for implementation are excellently *OR* very well *OR* well identified, qualified and, and appropriate mitigation measures are proposed

The consortium composition and expertise reflects the project's objectives and brings together the necessary disciplinary and inter-disciplinary knowledge, such as open science practices. The complementarity of the project consortium is excellent *OR* very good.

Recommendation: Consortium building



- Good balance of European countries
- Best consortium size between 10 and 20 partners
- Good balance of Academic, SME, Industry
- Public/parapublic national, european or international organisation is always improve credibility
- Each partner should be able to present at least 5 scientific publications
- Interest of administrative partner
- Develop potential work experience or synergies between partners
- Not forbidden to join 2 competitive consortium in the same call !

Last recommendations

- Use successful proposal as a template
- Construct a robust and well balanced consortium
- «tick the boxes» is more important than science
- The coordinator write the proposal
- Workpackage leaders write WP description
- Submit 2 days before the deadline

THANK YOU